In-house crystallography – increasing efficiency in drug discovery and development
Accelerate discovery, make the right decisions, improve efficiency
Single crystal X-ray diffraction (SC-XRD) provides detailed unambiguous structural information and plays a crucial role in the establishment of new drug targets and drives structure-based drug discovery, API synthesis, IND registration and new solid form development.
In-house SC-XRD has become substantially faster, simpler and more accessible due to developments in X-ray sources, detectors, crystallographic software and automation.
Modern instruments not only drive research, but their 24/7 accessibility and high uptime mean that they present a highly attractive ROI and can enhance the services provided by CROs.
This webinar will highlight the capabilities of state-of-the art in-house SC-XRD in drug discovery and development and explore the benefits of leveraging the right instrument for different research requirements. We will also consider how a modern SC-XRD facility can provide an attractive ROI and help improve your product quality.
Which topics will be covered?
- How in-house SC-XRD can accelerate target development and structure based drug discovery.
- How SC-XRD can be more routinely applied to guiding API synthesis resulting in better decision making and more efficient syntheses
- How easily SC-XRD can be applied to the development of novel and improved solid forms.
- How the right in-house SC-XRD platform can be cost-effective across the development chain.
Who should attend?
- Structural Biologists, Medicinal Chemists and Solid Form Scientists working in drug discovery and development: learn how modern in-house crystallography can drive your science.
- Heads of Research, Managers and Directors: gain insight into how modern facilities can improve the quality and timeliness of your product, provide a solid return on investment, and even generate additional revenue for your company.
Presenter: Dr. Vernon Smith (SC-XRD Business Development Manager, Bruker AXS)
